Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences HoldingsIART +0.94%71 EV-to-OCF is 36.52 as of Aug. 08, 2026, which is 25% above its 10-year median of 29.10. GuruFocus rates IART with a GF Score™ of 71/100 and a GF Value™ of $20.57 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks worse than 87.21% on this metric.
The historical rank and industry rank for Integra Lifesciences Holdings's EV-to-OCF or its related term are showing as below:
IART'
s EV-to-OCF Range Over the Past 10 Years
Min: 18.15 Med: 29.1 Max: 55.81
Current: 36.52
During the past 13 years, the highest EV-to-OCF of Integra Lifesciences Holdings was 55.81. The lowest was 18.15. And the median was 29.10.
IART's EV-to-OCF is ranked worse than 87.21% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs IART: 36.52
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Integra Lifesciences Holdings's PE Ratio (TTM) for today is calculated as:
Integra Lifesciences Holdings's share price for today is $17.243.
Integra Lifesciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.092.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Integra Lifesciences Holdings EV-to-OCF Related Terms
Integra Lifesciences Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Integra Lifesciences Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's EV-to-OCF falls into.
Integra Lifesciences Holdings's current Enterprise Value is $3,116 Mil.
Integra Lifesciences Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (IART) has a EV-to-OCF of 36.52 as of Aug. 08, 2026. This is 25% above median its historical median of 29.10. Over the past decade, Integra Lifesciences Holdings' EV-to-OCF has ranged from 18.15 to 55.81. According to the industry distribution chart, Integra Lifesciences Holdings ranks #743 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 87.2%.
Is Integra Lifesciences Holdings' EV-to-OCF too high?
Integra Lifesciences Holdings' current EV-to-OCF of 36.52 is 25% above median its 10-year median of 29.10. Over the past 10 years, this metric has ranged from a low of 18.15 to a high of 55.81. The Medical Devices & Instruments industry median EV-to-OCF is 7.84. Integra Lifesciences Holdings' value of 36.52 is 366.1% above this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #743 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integra Lifesciences Holdings has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' EV-to-OCF compare to ENOV and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #743 out of 852 companies for EV-to-OCF. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median EV-to-OCF is 7.84. Integra Lifesciences Holdings' value of 36.52 is 366.1% above this benchmark. Historically, Integra Lifesciences Holdings' own EV-to-OCF has ranged from 18.15 to 55.81 over the past decade. While the company's 10-year median is 29.10 vs. the industry median of 7.84, Integra Lifesciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current EV-to-OCF of 36.52 is 366.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current EV-to-OCF is 36.52, which is 25% above median its own 10-year median of 29.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.57, compared to a current price of $17.24 — trading 16.2% below its estimated fair value. The current EV-to-OCF is 36.52, which is 25% above median its 10-year median of 29.10 and 366.1% above the Medical Devices & Instruments industry median of 7.84. Integra Lifesciences Holdings' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current EV-to-OCF is 36.52 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $17.24 is trading 16.2% below its estimated GF Value™ of $20.57.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
EV-to-OCF: 36.52 (25% above median its 10-year median of 29.10)
GF Value™: $20.57 vs. price of $17.24 (16.2% below fair value)
Industry Position: 366.1% above the Medical Devices & Instruments median (#743 of 852)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
71GF Score
Get the complete analysis for IART
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
